Journal of Biological Chemistry
Volume 284, Issue 43, 23 October 2009, Pages 29559-29570
Journal home page for Journal of Biological Chemistry

Mechanisms of Signal Transduction
Diacylglycerol Kinase η Augments C-Raf Activity and B-Raf/C-Raf Heterodimerization*

https://doi.org/10.1074/jbc.M109.043604Get rights and content
Under a Creative Commons license
open access

The Ras/B-Raf/C-Raf/MEK/ERK signaling cascade is critical for the control of many fundamental cellular processes, including proliferation, survival, and differentiation. This study demonstrated that small interfering RNA-dependent knockdown of diacylglycerol kinase η (DGKη) impaired the Ras/B-Raf/C-Raf/MEK/ERK pathway activated by epidermal growth factor (EGF) in HeLa cells. Conversely, the overexpression of DGKη1 could activate the Ras/B-Raf/C-Raf/MEK/ERK pathway in a DGK activity-independent manner, suggesting that DGKη serves as a scaffold/adaptor protein. By determining the activity of all the components of the pathway in DGKη-silenced HeLa cells, this study revealed that DGKη activated C-Raf but not B-Raf. Moreover, this study demonstrated that DGKη enhanced EGF-induced heterodimerization of C-Raf with B-Raf, which transmits the signal to C-Raf. DGKη physically interacted with B-Raf and C-Raf, regulating EGF-induced recruitment of B-Raf and C-Raf from the cytosol to membranes. The DGKη-dependent activation of C-Raf occurred downstream or independently of the already known C-Raf modifications, such as dephosphorylation at Ser-259, phosphorylation at Ser-338, and interaction with 14-3-3 protein. Taken together, the results obtained strongly support that DGKη acts as a novel critical regulatory component of the Ras/B-Raf/C-Raf/MEK/ERK signaling cascade via a previously unidentified mechanism.

Cited by (0)

*

This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Northern Advancement Center for Science and Technology of Hokkaido, Japan, the Japan Diabetes Foundation, The Suhara Memorial Foundation, Novo Nordisk Pharma Ltd. (Japan), The Takeda Science Foundation, The Suzuken Memorial Foundation, and The Akiyama Foundation.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S7.